Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Apr

Today In Oncology

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Related Videos

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Long-Term Immunotherapy for Alveolar Soft Part Sarcoma

AMA Data Show Nearly 50 Percent of Surveyed Oncologists Reported Burnout in 2025

Unique Phase I NSCLC Trial Sites Decreasing in United States

Overall Survival With Addition of Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

Tislelizumab With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer